Featured Research

from universities, journals, and other organizations

Women Still Face Cancer Risk 25 Years After Treatment

Date:
October 28, 2007
Source:
BMJ-British Medical Journal
Summary:
Women are still at risk of developing invasive cancer of the cervix or vagina 25 years after being treated for precancerous lesions, according to a new study. Women who have had severe cell changes in the cervix and who have been operated on for them run twice the risk of developing cancer later in life, compared with other women. Cancer experts are now calling for cytological smears to be offered at regular intervals for at least 25 years after a woman has had severe dysplasia/CIS (carcinoma in situ).

Women are still at risk of developing invasive cancer of the cervix or vagina 25 years after being treated for pre-cancerous lesions, according to a study published today on the British Medical Journal website.

Related Articles


Cancer experts are now calling for cytological smears to be offered at regular intervals for at least 25 years after a woman has had severe dysplasia/CIS (carcinoma in situ).

CIS is not cancer but close to it as some cells look cancerous but are superficially in the mucosa (the soft skin-like layer that lines many body cavities such as the nasal and genital passages) and not in any tissue.

Researchers in Sweden studied data from the National Swedish Cancer Register, which included information recorded between 1958 and 2002 on 132,493 women who had a diagnosis of severe dysplasia/CIS.

They found that 881 women had developed cervical cancer and 111 women had vaginal cancer more than one year after the CIS diagnosis.

Women with such a diagnosis are more than twice as likely to develop cancer as the general female population.

They also found that there was an increasing risk of cervical cancer if the woman was older at the time of diagnosis, with a much higher risk for women aged over 50.

The risk also grew as the decades went by as the researchers found that women were twice as likely to develop invasive cervical cancer after diagnosis of CIS if that diagnosis was made in the period 1991-2000 as in the period 1958-1970. This could be due to changes in the forms of treatment in different decades.

The observed number of cases of women who developed vaginal cancer was almost seven times higher than expected.

The authors say: "Although most women with high-grade dysplasia have been protected from invasive cancer it must be considered a failure of the medical service when women participate in screening, their pre-cancerous lesions are found and they subject themselves to treatment of those lesions, presumably participate in follow-up programmes and still develop invasive cancer."

They conclude that follow-up care has, so far, been insufficient and women should be offered cytological smears at regular intervals for at least 25 years after treatment. Long term follow up should not stop for women when they reach the age of 60 if they were older than 35-40 at the time of treatment for CIS.

This view is reiterated in accompanying BMJ editorial, which suggests that women treated for CIN3 should have long term screening, even if beyond the normal age limit of regular screening.


Story Source:

The above story is based on materials provided by BMJ-British Medical Journal. Note: Materials may be edited for content and length.


Cite This Page:

BMJ-British Medical Journal. "Women Still Face Cancer Risk 25 Years After Treatment." ScienceDaily. ScienceDaily, 28 October 2007. <www.sciencedaily.com/releases/2007/10/071025174653.htm>.
BMJ-British Medical Journal. (2007, October 28). Women Still Face Cancer Risk 25 Years After Treatment. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2007/10/071025174653.htm
BMJ-British Medical Journal. "Women Still Face Cancer Risk 25 Years After Treatment." ScienceDaily. www.sciencedaily.com/releases/2007/10/071025174653.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com
From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

Newsy (Nov. 25, 2014) — The US FDA is announcing new calorie rules on Tuesday that will require everywhere from theaters to vending machines to include calorie counts. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins